BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 7969053)

  • 1. Biguanide derivatives: agonist pharmacology at 5-hydroxytryptamine type 3 receptors in vitro.
    Morain P; Abraham C; Portevin B; De Nanteuil G
    Mol Pharmacol; 1994 Oct; 46(4):732-42. PubMed ID: 7969053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of serotonin 5-HT3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding.
    Hoyer D; Neijt HC
    Mol Pharmacol; 1988 Mar; 33(3):303-9. PubMed ID: 3352595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels.
    Hargreaves AC; Gunthorpe MJ; Taylor CW; Lummis SC
    Mol Pharmacol; 1996 Nov; 50(5):1284-94. PubMed ID: 8913360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
    Cappelli A; Anzini M; Vomero S; Mennuni L; Makovec F; Doucet E; Hamon M; Bruni G; Romeo MR; Menziani MC; De Benedetti PG; Langer T
    J Med Chem; 1998 Feb; 41(5):728-41. PubMed ID: 9513601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
    Leysen JE; Gommeren W; Heylen L; Luyten WH; Van de Weyer I; Vanhoenacker P; Haegeman G; Schotte A; Van Gompel P; Wouters R; Lesage AS
    Mol Pharmacol; 1996 Dec; 50(6):1567-80. PubMed ID: 8967979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors.
    Oz M; Zhang L; Rotondo A; Sun H; Morales M
    Synapse; 2003 Dec; 50(4):303-13. PubMed ID: 14556235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full and partial agonists induce distinct desensitized states of the 5-HT3 receptor.
    van Hooft JA; Vijverberg HP
    J Recept Signal Transduct Res; 1997; 17(1-3):267-77. PubMed ID: 9029495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ca2+ permeability of cloned and native 5-hydroxytryptamine type 3 receptors.
    Hargreaves AC; Lummis SC; Taylor CW
    Mol Pharmacol; 1994 Dec; 46(6):1120-8. PubMed ID: 7808432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrimination in 5-HT(3) receptor binding in murine brain and cultured cell preparations.
    Zhang ZJ; Trivedi BL; de Paulis T; Schmidt DE; Hewlett WA
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):123-32. PubMed ID: 11819030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral effects of the 5-hydroxytryptamine3 receptor agonists 1-phenylbiguanide and m-chlorophenylbiguanide in rats.
    Higgins GA; Joharchi N; Sellers EM
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1440-9. PubMed ID: 8450478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
    Tapia I; Alonso-Cires L; López-Tudanca PL; Mosquera R; Labeaga L; Innerárity A; Orjales A
    J Med Chem; 1999 Jul; 42(15):2870-80. PubMed ID: 10425096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The agonist properties of m-chlorophenylbiguanide and 2-methyl-5-hydroxytryptamine on 5-HT3 receptors in N1E-115 neuroblastoma cells.
    Sepúlveda MI; Lummis SC; Martin IL
    Br J Pharmacol; 1991 Oct; 104(2):536-40. PubMed ID: 1797317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
    Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C; Kleven M
    J Med Chem; 1999 May; 42(9):1648-60. PubMed ID: 10229633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT3-like receptors in the rat medial prefrontal cortex: further pharmacological characterization.
    Edwards E; Hampton E; Ashby CR; Zhang J; Wang RY
    Brain Res; 1996 Sep; 733(1):21-30. PubMed ID: 8891244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a 5-hydroxytryptamine receptor in mouse neuroblastoma N18TG2 cells.
    Unsworth CD; Molinoff PB
    J Pharmacol Exp Ther; 1994 Apr; 269(1):246-55. PubMed ID: 8169832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium influx through presynaptic 5-HT3 receptors facilitates GABA release in the hippocampus: in vitro slice and synaptosome studies.
    Turner TJ; Mokler DJ; Luebke JI
    Neuroscience; 2004; 129(3):703-18. PubMed ID: 15541891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular cloning and pharmacological characterization of serotonin 5-HT(3A) receptor subtype in dog.
    Jensen TN; Nielsen J; Frederiksen K; Ebert B
    Eur J Pharmacol; 2006 May; 538(1-3):23-31. PubMed ID: 16647053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The loop C region of the murine 5-HT3A receptor contributes to the differential actions of 5-hydroxytryptamine and m-chlorophenylbiguanide.
    Suryanarayanan A; Joshi PR; Bikádi Z; Mani M; Kulkarni TR; Gaines C; Schulte MK
    Biochemistry; 2005 Jun; 44(25):9140-9. PubMed ID: 15966738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors.
    Yang D; Soulier JL; Sicsic S; Mathé-Allainmat M; Brémont B; Croci T; Cardamone R; Aureggi G; Langlois M
    J Med Chem; 1997 Feb; 40(4):608-21. PubMed ID: 9046352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system.
    Adham N; Ellerbrock B; Hartig P; Weinshank RL; Branchek T
    Mol Pharmacol; 1993 Mar; 43(3):427-33. PubMed ID: 8095694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.